ClinicalTrials.gg
RecruitingNCT01630421ACCUpdated Apr 15, 2026

Genetic and Functional Analysis of Aplasia Cutis Congenital (ACC)

An observational study in Aplasia Cutis Congenita, sponsored by UConn Health. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by UConn Health · Observational

Study type
Observational
Model
Family-based
Time perspective
Prospective
Enrollment
600
Sex
All
01

Study summary

The goal of this research study is to identify genes and regulatory elements on chromosomes that cause ACC. The investigators also study tissue samples from patients to learn about the processes that lead to this disorder.

Read the detailed description

Aplasia cutis congenita (ACC) or congenital scalp defect is a very rare disorder that affects bone and skin. The definition for ACC is the localized absence of (normal) skin at the time of birth (congenital). The skin appears thinner and the underlying structures are visible. We study mostly the isolated form of ACC with the lesion often being at the vertex of the skull (at or close to the top of the skull). The bone underlying the lesion is sometimes thinner as well.

For this study we will:

  • Send out study participation kits and consent by phone
  • Collect a saliva sample from eligible individuals
  • Obtain information regarding ACC
  • Document disorder with photos and doctor's letters
  • If patients undergo surgery for ACC we ask to obtain some tissue that would otherwise be discarded
  • Isolate DNA from the saliva sample
  • Perform genetic analyses of the DNA with the most up-to-date methods available to identify genetic variations
  • Study in the laboratory why the genetic variations cause the disorder
02

Conditions studied

  • Aplasia Cutis Congenita

Browse trials for

Keywords

  • Aplasia cutis congenita
  • bone
  • osteoblast
  • osteoclast
  • skin
03

In context

Ectodermal Dysplasia

10 studies on the registry are indexed under Ectodermal Dysplasia; 6 are open to participants now.

Browse Ectodermal Dysplasia studies →

Lead sponsor

UConn Health is the lead sponsor of 187 studies on the registry; 18 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 7 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals with diagnosed ACC

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ACC; unaffected individuals only if part of a participating ACC family

Exclusion criteria

Exclusion Criteria:

  • No ACC unaffected individuals only as part of a participating ACC family
05

Study design

Observational model
Family-based
Time perspective
Prospective
Enrollment
600 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • affected, unaffected

    Individuals with diagnosed ACC

06

What researchers measure

Primary outcomes

  1. Identification of genetic elements

    The goal is to identify relevant genes or genetic elements that cause the disease or contribute to the disease progression and severity.

    Time frame: at time of identification

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Levine SM, Reformat DD, Thorne CH. Cutis aplasia: perioperative management and case report. Am J Crit Care. 2012 May;21(3):212-5. doi: 10.4037/ajcc2012904. PubMed 22549580 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01630421
Lead sponsor
UConn Health
Responsible party
Ernst Reichenberger (Assoc. Prof., UConn Health) — Principal investigator
First posted
Jun 28, 2012
Start date
Apr 2009
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Apr 15, 2026

Study contacts

Ernst J Reichenberger, PhD
Contact
reichenberger@uchc.edu
860-679-2062
Ernst J Reichenberger, PhD
principal investigator · UConn Health

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion